Niacin-induced hyperglycemia is partially mediated via niacin receptor GPR109a in pancreatic islets

Molecular and Cellular Endocrinology

Volumn 404, Issue , 2015, Pages 56-66

  Chen, Lihua ^a   So, Wing Yan ^a   Li, Stephen Y T ^a   Cheng, Qianni ^a   Boucher, Barbara J ^b   Leung, Po Sing ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

G protein coupled receptor; Glucose homeostasis; Insulin secretion; Islet function; Pancreas; Reactive oxygen species

Indexed keywords

CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 109A; GLUCOSE; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2; ANTILIPEMIC AGENT; HCAR2 PROTEIN, MOUSE; HCAR2 PROTEIN, RAT; INSULIN; ION CHANNEL; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL UNCOUPLING PROTEIN 2; NICOTINIC RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HYPERGLYCEMIA; INSULIN RELEASE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL LINE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; MEMBRANE POTENTIAL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SECRETION (PROCESS);

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; GLUCOSE; HYPERGLYCEMIA; HYPOLIPIDEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; ION CHANNELS; MEMBRANE POTENTIALS; MICE; MICE, INBRED C57BL; MITOCHONDRIAL PROTEINS; NIACIN; OBESITY; PPAR GAMMA; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC;

EID: 84922250464     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.01.029     Document Type: Article

References (46)

1. Abbate S.L., Brunzell J.D. Pathophysiology of hyperlipidemia in diabetes mellitus. J. Cardiovasc. Pharmacol 1990, 16(Suppl. 9):S1-S7.
2. Benavente C.A., Jacobson E.L. Niacin restriction upregulates NADPH oxidase and reactive oxygen species (ROS) in human keratinocytes. Free Radic. Biol. Med 2008, 44(4):527-537.
3. Benyo Z., Gille A., Bennett C.L., Clausen B.E., Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol. Pharmacol 2006, 70(6):1844-1849.
4. Bugge A., Siersbaek M., Madsen M.S., Gondor A., Rougier C., Mandrup S. A novel intronic peroxisome proliferator-activated receptor gamma enhancer in the uncoupling protein (UCP) 3 gene as a regulator of both UCP2 and -3 expression in adipocytes. J. Biol. Chem 2010, 285(23):17310-17317.
5. Chang A.M., Smith M.J., Galecki A.T., Bloem C.J., Halter J.B. Impaired beta-cell function in human aging: response to nicotinic acid-induced insulin resistance. J. Clin. Endocrinol. Metab 2006, 91(9):3303-3309.
6. Cheng Q., Law P.K., de Gasparo M., Leung P.S. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J. Pharmacol. Exp. Ther 2008, 327(3):683-691.
7. Cheng Q., Boucher B.J., Leung P.S. Modulation of hypovitaminosis D-induced islet dysfunction and insulin resistance through direct suppression of the pancreatic islet renin-angiotensin system in mice. Diabetologia 2013, 56(3):553-562.
8. Clement S., Braithwaite S.S., Magee M.F., Ahmann A., Smith E.P., Schafer R.G., et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004, 27(2):553-591.
9. Cossarizza A., Salvioli S. Flow cytometric analysis of mitochondrial membrane potential using JC-1. Curr. Protoc. Cytom 2001, 13:1-7. Chapter 9, Unit 9.14.
10. Danaei G., Finucane M.M., Lu Y., Singh G.M., Cowan M.J., Paciorek C.J., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378(9785):31-40.
11. Del Prato S., Marchetti P., Bonadonna R.C. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 2002, 51(Suppl. 1):S109-S116.
12. Gaidarov I., Chen X., Anthony T., Maciejewski-Lenoir D., Liaw C., Unett D.J. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential. Cell. Signal 2013, 25(10):2003-2016.
13. Garg A., Grundy S.M. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. J. Am. Med. Assoc 1990, 264(6):723-726.
14. Goldberg R.B., Jacobson T.A. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin. Proc 2008, 83(4):470-478.
15. 2+ in the pancreatic b-cell. Biochem. Biophys. Res. Commun 1988, 151(3):1299-1304.
16. Guyton J.R. Effect of niacin on atherosclerotic cardiovascular disease. Am. J. Cardiol 1998, 82(12):18U-23U.
17. Ha C.M., Park D., Han J.K., Jang J.I., Park J.Y., Hwang E.M., et al. Calcyon forms a novel ternary complex with dopamine D1 receptor through PSD-95 protein and plays a role in dopamine receptor internalization. J. Biol. Chem 2012, 287(38):31813-31822.
18. Han S.J., Kang E.S., Hur K.Y., Kim H.J., Kim S.H., Yun C.O., et al. Rosiglitazone inhibits early stage of glucolipotoxicity-induced beta-cell apoptosis. Horm. Res 2008, 70(3):165-173.
19. Jhala U.S., Canettieri G., Screaton R.A., Kulkarni R.N., Krajewski S., Reed J., et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 2003, 17(13):1575-1580.
20. Joseph J., Koshkin V., Zhang C.Y., Wang J., Lowell B.B., Chan C.B., et al. Uncoupling protein 2 knockout mice have enhanced insulin secretory capacity after a high-fat diet. Diabetes 2002, 51(11):3211-3219.
21. Joseph J.W., Koshkin V., Saleh M.C., Sivitz W.I., Zhang C.Y., Lowell B.B., et al. Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression. J. Biol. Chem 2004, 279(49):51049-51056.
22. Kamanna V.S., Kashyap M.L. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?. Am. J. Cardiol 2007, 100(11A):S53-S61.
23. Kamanna V.S., Kashyap M.L. Mechanism of action of niacin. Am. J. Cardiol 2008, 101(8A):S20-S26.
24. Kanda Y., Shimoda M., Hamamoto S., Tawaramoto K., Kawasaki F., Hashiramoto M., et al. Molecular mechanism by which pioglitazone preserves pancreatic b-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARg agonist. Am. J. Physiol. Endocrinol. Metab 2009, 298(2):E278-E286.
25. Knowles H.J., Poole R.T., Workman P., Harris A.L. Niacin induces PPARg expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem. Pharmacol 2006, 71(5):646-656.
26. 2+ and cAMP signaling in the insulin-secreting MIN6 beta-cell line. J. Biol. Chem 2005, 280(35):31294-31302.
27. Letiexhe M.R., Scheen A.J., Gerard P.L., Desaive C., Lefebvre P.J. Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects. Int. J. Obes. Relat. Metab. Disord 1994, 18(5):295-300.
28. Li H.M., Zhang M., Xu S.T., Li D.Z., Zhu L.Y., Peng S.W., et al. Nicotinic acid inhibits glucose-stimulated insulin secretion via the G protein-coupled receptor PUMA-G in murine islet β cells. Pancreas 2011, 40(4):615-621.
29. Linke A., Sonnabend M., Fasshauer M., Hollriegel R., Schuler G., Niebauer J., et al. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis 2009, 205(1):207-213.
30. Lukasova M., Malaval C., Gille A., Kero J., Offermanns S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J. Clin. Invest 2011, 121(3):1163-1173.
31. McCulloch D.K., Kahn S.E., Schwartz M.W., Koerker D.J., Palmer J.P. Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons. J. Clin. Invest 1991, 87(4):1395-1401.
32. McQuaid T.S., Saleh M.C., Joseph J.W., Gyulkhandanyan A., Manning-Fox J.E., MacLellan J.D., et al. cAMP-mediated signaling normalizes glucose-stimulated insulin secretion in uncoupling protein-2 overexpressing b-cells. J. Endocrinol 2006, 190(3):669-680.
33. Medvedev A.V., Robidoux J., Bai X., Cao W., Floering L.M., Daniel K.W., et al. Regulation of the uncoupling protein-2 gene in INS-1 beta-cells by oleic acid. J. Biol. Chem 2002, 277(45):42639-42644.
34. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997, 349(9064):1498-1504.
35. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32(1):193-203.
36. Oh Y.T., Oh K.S., Choi Y.M., Jokiaho A., Donovan C., Choi S., et al. Continuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissue. Am. J. Physiol. Endocrinol. Metab 2011, 300(6):E1012-E1021.
37. Pereira J.N. The plasma free fatty acid rebound induced by nicotinic acid. J. Lipid Res 1967, 8(3):239-244.
38. Plaisance E.P., Lukasova M., Offermanns S., Zhang Y., Cao G., Judd R.L. Niacin stimulates adiponectin secretion through the GPR109A receptor. Am. J. Physiol. Endocrinol. Metab 2009, 296(3):E549-E558.
39. Rasouli N., Hale T., Kahn S.E., Spencer H.J., Elbein S.C. Effects of short-term experimental insulin resistance and family history of diabetes on pancreatic beta-cell function in nondiabetic individuals. J. Clin. Endocrinol. Metab 2005, 90(10):5825-5833.
40. Ravnskjaer K., Boergesen M., Rubi B., Larsen J.K., Nielsen T., Fridriksson J., et al. Peroxisome proliferator-activated receptor alpha (PPARalpha) potentiates, whereas PPARgamma attenuates, glucose-stimulated insulin secretion in pancreatic beta-cells. Endocrinology 2005, 146(8):3266-3276.
41. Rubic T., Trottmann M., Lorenz R.L. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem. Pharmacol 2004, 67(3):411-419.
42. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit. Med. J. 2000, 321(7258):405-412.
43. Tunaru S., Kero J., Schaub A., Wufka C., Blaukat A., Pfeffer K., et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med 2003, 9(3):352-355.
44. Vosper H. Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. Br. J. Pharmacol 2009, 158(2):429-441.
45. Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid. Redox Signal 2008, 10(2):179-206.
46. Zhang C.Y., Baffy G., Perret P., Krauss S., Peroni O., Grujic D., et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 2001, 105(6):745-755.